Ignite Creation Date:
2024-05-06 @ 4:17 PM
Last Modification Date:
2024-10-26 @ 2:07 PM
Study NCT ID:
NCT04939857
Status:
UNKNOWN
Last Update Posted:
2021-06-25
First Post:
2021-05-27
Brief Title:
Effect of Trimetazidine on Radiotherapy-induced Heart Damage
Sponsor:
Peking University Third Hospital
Organization:
Peking University Third Hospital
Study Overview
Official Title:
Effect of Trimetazidine on Radiotherapy-induced Heart Damage in Lung Tumor Patients Treated With Stereotactic Body Radiotherapy
Status:
UNKNOWN
Status Verified Date:
2021-06
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized controlled trial 80 patients with thoracic radiotherapy will be included Participants will be randomly divided into experimental group or control group Before radiotherapy echocardiography 2D STE CK CK-MB cTnT NT-proBNP electrocardiogram ECG and hs-CRP will be detected During subsequent follow-up echocardiography 2D STE CK CK-MB cTnT NT-proBNP ECG and hs-CRP will be collected at every follow-up time
Detailed Description:
This is a randomized controlled trial 80 patients with thoracic radiotherapy will be included in Peking University Third Hospital from May 15 2021 to August 31 2022 Participants will be randomly divided into experimental group or control group Before radiotherapy echocardiography 2D STE CK CK-MB cTnT NT-proBNP electrocardiogram ECG and hs-CRP will be detected All participants will be followed up after completion of RT 3 months after RT 6 months after RT and 12 months after RT During subsequent follow-up echocardiography 2D STE CK CK-MB cTnT NT-proBNP ECG and hs-CRP will be collected at every follow-up time
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None